Subscribe
Funding & M&A
3 min read

Pivotal Group buys animal health manufacturer Precision Science

Pivotal Group, a Phoenix investment firm, has acquired Precision Science, a Phoenix animal health contract manufacturer founded in 1989. Pivotal said a 130,000-square-foot North Phoenix plant, two-thirds complete, will add three manufacturing lines and expand into liquids.

Written by
Roy Ben-Tzvi
Published on
November 17, 2026
Pivotal Group buys animal health manufacturer Precision Science

Pivotal Group, a Phoenix investment firm founded by Francis Najafi, has acquired Precision Science, a Phoenix animal health contract manufacturer founded in 1989 that is finishing a 130,000-square-foot plant in North Phoenix. Pivotal said the deal is its first acquisition in animal health. It did not give a purchase price.

Precision Science makes pharmaceuticals, medicated feed additives and supplements for global animal health companies, supplement brands and entrepreneurs. Pivotal said it has invested in manufacturing capacity, technology and people since closing, and that the new platform keeps a focus on quality, safety and regulatory compliance with an FDA-registered facility, an in-house laboratory and quality systems.

Pivotal takes over a 1989 contract manufacturer in Phoenix

Najafi called the deal "an exciting opportunity for Pivotal Group to build a leading platform focused on animal health starting with supplements and pharmaceuticals." He said Pivotal was drawn to the growing animal health market and to Precision Science's commitment to quality and innovation.

Pivotal describes itself as a private equity investor and builder of companies. It has invested in the technology companies Network Solutions, Global Capacity, Global Meet and MegaPath, and it owns and operates Promontory, a luxury mountain community in Park City, Utah.

Precision Science's own site lists powders, pelletizing, soft chews, extrusion, roll compaction and granulation among its capabilities, along with analytical testing and packaging, and cites $3M invested in infrastructure. The National Animal Supplement Council lists the company as a preferred supplier and describes an FDA, EPA and organic certified facility. Bryan Vincent, CEO of Precision Science, is the council's listed contact.

Vincent said "Our clients are asking us to look ahead" and that Pivotal's backing gives the company resources to invest in people, product development and manufacturing capabilities.

Other US animal drug plants have changed hands this year

Bimeda acquired selected non-sterile manufacturing assets from Dechra at a facility in Pomona, California, and said the deal adds capacity and expands its U.S. production base. Parnell completed its purchase of Noble Pharma, an FDA- and DEA-accredited manufacturer in Menomonie, Wisconsin, whose product list includes suspensions, liquids, tablets, boluses, powders, gels, pastes, creams and ointments.

Liquids are a format Pivotal says the new North Phoenix plant will add. Noble Pharma already lists liquids, and Parnell sells animal health products for companion and production animals in 10 countries.

US-made product is also a policy topic. FDA's Center for Veterinary Medicine opened a voluntary pilot that speeds review of animal drug applications when both the finished product and its active ingredient are made in the US, as we reported in July. Contract plants also sit behind brand names, as in our coverage of Revival Animal Health's August milk replacer recall, which the company traced to a third-party manufacturer.

For animal health sponsors and supplement brands that outsource production, the deal adds a Phoenix site with a private equity owner and a plant under construction to the list of US contract options. Najafi said Pivotal will support the platform with the capital and resources needed to expand capabilities.

The unfinished North Phoenix plant sets the next milestone

Pivotal said the highly automated North Phoenix plant is two-thirds complete. It will add three manufacturing lines, expand into liquids, and increase analytical, product development, storage and logistics capacity, in addition to Precision Science's existing facilities.

Pivotal also said the new plant and expanded capabilities will create opportunities to hire additional manufacturing and leadership talent in Phoenix.

Pivotal's stated plan starts with supplements and pharmaceuticals in Phoenix.

Source: Pivotal Group via PR Newswire

Every pet deal we track is in The Underbite's pet industry M&A tracker.

See every deal in the Pet Industry M&A Tracker →

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
CompanAIn names animal health veteran Brük Herbst COO
People
4 min read

CompanAIn names animal health veteran Brük Herbst COO

CompanAIn, a Charleston company building an AI-native health platform for dogs, cats and horses, named Brük Herbst chief operating officer. Herbst, a former IDEXX, Covetrus and Zomedica executive, will lead its move from platform validation to commercial scale.

Read article
Read article
Loyal taps Argenta for early development of its LOY-003 dog drug
Strategy
3 min

Loyal taps Argenta for early development of its LOY-003 dog drug

Loyal has brought in animal health contract manufacturer Argenta to support early-stage development of LOY-003, its daily pill for large and giant-breed dogs.

Read article
Read article
Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment
Regulatory
3 min read

Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment

Vetoquinol won FDA approval for Felpreva, a prescription topical parasiticide for cats applied four times a year, with vets able to order in 2027.

Read article
View all articles